Related by context. All words. (Click for frequent words.) 64 NKTR 64 MT# MEDI 63 Nanobody 63 ARRY 63 INGN 62 AEZS 62 MEK inhibitor 61 CUDC 61 GLPG# 61 phase IIa clinical 61 Sapacitabine 61 histone deacetylase HDAC inhibitor 61 NOXXON 61 EndoTAG TM -1 61 EndoTAG 60 PRTX 60 pan HDAC inhibitor 60 Anticalin R 60 HCV protease inhibitor 60 polymerase inhibitor 60 CRx 60 mertansine 60 PDE4 inhibitor 60 Azedra 60 Phase Ib II 60 Lu AA# 60 huN# DM1 59 targeted radiotherapeutic 59 orally bioavailable 59 MORAb 59 TG# [003] 59 HDAC Inhibitor 59 Sym# 59 PEG SN# 59 oral antiviral 59 Bezielle 59 JAK inhibitor 59 HuLuc# 59 RhuDex ® 59 ISIS # 59 SUVN 59 Kahalalide F 59 JVRS 59 Archexin 59 YONDELIS 58 PSMA ADC 58 Aflibercept 58 NVA# 58 Maribavir 58 DermaVir Patch 58 AEGR 58 liposomal formulation 58 Guanilib 58 Phase Ib clinical 58 Pazopanib 58 R#/MEM # 58 humanized monoclonal antibody 58 CEQ# 58 AEG# 58 bendamustine 58 Carfilzomib 58 Evotec AG 58 lumiliximab 58 PF # [001] 58 WILEX 58 Diatos 58 ATL# [001] 58 Phase IIa clinical 58 targeting CD# 58 thymalfasin 58 phase IIb clinical 58 Exelixis XL# 58 belinostat 58 OXi# 58 Pradefovir 58 multi kinase inhibitor 58 Laquinimod 58 IMGN# 58 Aplidin 57 IAP inhibitors 57 pomalidomide 57 Cloretazine 57 oral prodrug 57 HQK 57 INCB# [001] 57 ALTU 57 Scancell 57 CoFactor 57 Debio 57 VQD 57 VentiRx 57 AAG geldanamycin analog 57 Vidofludimus 57 4SC AG 57 Onconase 57 YONDELIS R 57 Phase Ib 57 Mipomersen 57 atacicept 57 HuMax CD4 57 BAY #-# 57 CYT# 57 ADXS# 57 immatics 57 Relypsa 57 Symphogen 57 Phase Ib study 57 reslizumab 57 favorable pharmacokinetic profile 57 Alocrest 57 Allovectin 7 R 57 anticancer agent 56 TREANDA 56 Axiogenesis 56 ELND# 56 OncoVEX GM CSF 56 VEGF Trap 56 Phase IIa trials 56 Gemin X 56 VitiGam 56 NXL# 56 vascular disrupting agent 56 Taligen Therapeutics 56 CERE 56 HGS ETR1 56 CD# antibody [001] 56 HuMax CD# 56 PARP inhibitor 56 Fresenius Biotech 56 OncoGel 56 otelixizumab 56 RGB # 56 obatoclax 56 relapsed multiple myeloma 56 InNexus Biotechnology 56 resolvin 56 GW# [003] 56 PsychoGenics 56 triphendiol 56 telaprevir VX 56 PRT# 56 PEP# [003] 56 Symadex 56 LHRH antagonist 56 mapatumumab 56 Onalta 56 tesmilifene 56 nucleoside analog 56 HGS# 56 CCR5 antagonist 56 TBC# 56 ENMD # 56 preclinically 56 Angiocept 56 receptor tyrosine kinase inhibitor 56 carfilzomib 56 CD# monoclonal antibody 56 Versartis 56 ESBATech 56 Panzem 56 Annamycin 56 CD4 monoclonal antibody 56 Phase IIa 56 Pancreate 56 Omacetaxine 56 Luteinizing Hormone Releasing Hormone 56 PD LID 56 IMC A# 56 XmAb# 56 Zalypsis 56 sapacitabine 56 Irinotecan 56 Vilazodone 56 Santhera 56 Anticalin 56 elotuzumab 56 AVONEX ® 56 dacetuzumab 55 MKC# MKC# PP 55 phase IIa 55 PSN# [002] 55 Amrubicin 55 Phase Ib clinical trials 55 selective orally bioavailable 55 Safinamide 55 pradefovir 55 initiate Phase 1b 55 entinostat 55 tubulin inhibitor 55 DAVANAT 55 Arno Therapeutics 55 ELACYT 55 Allovectin 7 55 Tyrima 55 GSK# [001] 55 non nucleoside inhibitor 55 Serdaxin 55 Phase 2a trial 55 Ablynx 55 ORMD 55 histone deacetylase HDAC 55 anticancer compound 55 IMA# 55 Cellzome 55 INT# [002] 55 TRO# 55 Scil Proteins 55 Traficet EN 55 ATL/TV# 55 ganetespib 55 DAVANAT R 55 Clinuvel 55 cathepsin K inhibitor 55 IRX 2 55 Nanobody ® 55 BioInvent 55 Vitaxin 55 pharmacodynamic profile 55 HspE7 55 CCR9 antagonist 55 phase IIb 55 FOLOTYN ® 55 solithromycin 55 Varespladib 55 Epratuzumab 55 ARQ 55 ChemoCentryx 55 JAK inhibitors 55 SYGNIS 55 Alligator Bioscience AB 55 pan histone deacetylase 55 Vandetanib 55 Aurora kinase inhibitor 55 AP# [003] 55 Pimavanserin 55 Affimed Therapeutics AG 55 huC# DM4 55 Hsp# inhibitor 55 Cloretazine R VNP#M 55 subcutaneously administered 55 Onrigin 55 Posiphen 55 GammaCan 55 PHX# 55 CXA 55 Aegera 55 Aplidin R 55 PLX# 55 topical ophthalmic 55 PDE# inhibitors 55 BioAlliance Pharma 55 seliciclib CYC# 55 long acting muscarinic 55 LY# [002] 55 CR# vcMMAE 55 FluCide 55 Phase 1b 55 BAL# [002] 55 Trofex 55 EOquin TM 55 nicotinic alpha 7 55 Phase 2b trial 55 drug conjugate 55 Nexavar ® 55 KSP inhibitor 55 OMP #M# 55 Multiple Ascending Dose 55 Curaxin 55 ANAVEX #-# [003] 55 Proteo 55 novel peptide 55 ZYBRESTAT 55 Daclizumab 54 novel immunomodulatory 54 therapeutic antibody 54 Affimed 54 cancer immunotherapies 54 MGCD# [001] 54 ALN TTR# 54 omacetaxine 54 Avila Therapeutics 54 Voreloxin 54 Tarvacin 54 Amplimexon 54 Mpex 54 CIMZIA TM 54 TACI Ig 54 Phase III randomized controlled 54 Civacir 54 Cutanea 54 AQ4N 54 Addex Pharmaceuticals 54 Molecular Insight 54 axitinib 54 PXD# 54 Proteo Biotech AG 54 investigational humanized monoclonal antibody 54 Oxytrex TM 54 Myocet 54 Aviptadil 54 RDEA# 54 Phase #/#a 54 drug GLPG# 54 Virulizin ® 54 Locteron 54 isoform selective 54 CYC# 54 Phase 1b trial 54 INNO 54 neuraminidase inhibitor 54 antibody MAb 54 ZOLINZA 54 TLR9 agonist 54 davunetide intranasal AL 54 docetaxel Taxotere R 54 AEterna 54 epothilone 54 SRT# [003] 54 phase Ib 54 Dalbavancin 54 PRX# 54 therapeutic monoclonal antibody 54 THR beta agonist 54 highly selective adenosine 54 Phase 2a 54 Tarmogen 54 Harbor BioSciences 54 Actilon 54 systemic RNAi therapeutic 54 MGd 54 acyclovir Lauriad R 54 lorvotuzumab mertansine 54 iCo 54 Shigamabs ® 54 rNAPc2 54 Panzem R NCD 54 decitabine 54 preclinical efficacy 54 Ziopharm 54 Phase 1b clinical 54 ocrelizumab 54 mAb 54 antisense drug 54 CBLC# 54 AKT inhibitor 54 MAGE A3 ASCI 54 proteasome inhibitor 54 orally administered inhibitor 54 selective androgen receptor modulator 54 rilonacept 54 CCX# 54 volociximab 54 Alpharadin 54 Dacogen injection 54 Galenea 54 MediGene 54 alvespimycin 54 humanized antibody 54 Ixabepilone 54 Astex 54 EndoTAGTM 1 54 GALNS 54 GlycArt 54 OHR/AVR# 54 humanized monoclonal 54 ThermoDox ® 54 Æterna Zentaris 54 Clavis Pharma 54 Triolex 54 Aurora kinase 54 radiation sensitizer 54 ESBA# 54 ALKS 54 KemPharm 54 enzastaurin 54 Removab 54 elvucitabine 54 DP b# 54 humanized anti 54 Degarelix 54 IAP inhibitor 54 StemEx R 54 Oral NKTR 54 HCD# [002] 54 oral ridaforolimus 54 PEGylated Fab fragment 54 torezolid 54 Cethromycin 54 iSONEP 54 Azixa 54 PI3K inhibitor 54 BiPar 54 orally dosed 54 MT#/MEDI-# 54 Enanta 54 Enzastaurin 53 metaglidasen 53 Glufosfamide 53 Biovitrum 53 NOVAVAX 53 Tesmilifene 53 PEG Interferon lambda 53 injectable formulation 53 GSK '# 53 ActivX 53 Meets Primary Endpoint 53 eniluracil 53 prostone 53 BZL# 53 ponatinib 53 Cetrorelix 53 IPL# 53 CureVac 53 tanespimycin 53 Summary Genmab 53 ThermoDox R 53 vidofludimus 53 XOMA 53 vemurafenib 53 multicenter Phase 53 QuatRx 53 randomized controlled Phase 53 acting muscarinic antagonist 53 neratinib 53 Synavive 53 oral Hsp# inhibitor 53 Zybrestat 53 Zentaris GmbH 53 JAK1 53 Menadione 53 histone deacetylase inhibitor 53 Bicifadine 53 Allovectin 7 ® 53 bevacizumab Avastin ® 53 renin inhibitor 53 EyeGate 53 Virulizin R 53 Addrenex 53 pitavastatin 53 Pharnext 53 anti amnesic 53 Fodosine 53 Phase 1a 53 Elocalcitol 53 Dynogen 53 Tarceva TM 53 regorafenib 53 4SC AG ISIN DE# 53 Hedgehog pathway inhibitor 53 KRN# 53 Xanafide 53 EnVivo 53 Asentar 53 Anthim 53 elacytarabine 53 PrevOnco 53 lexidronam injection 53 RPL# 53 ExonHit 53 BioWa 53 MGCD# [002] 53 Iluvien ® 53 Vion Pharmaceuticals 53 sorafenib tablets 53 Taspoglutide 53 Helsinn Healthcare 53 Cimzia ® certolizumab pegol 53 PSN# [001] 53 TELINTRA 53 Transave 53 HGS ETR2 53 Nuron Biotech 53 ATHX 53 ITMN 53 non nucleoside HCV 53 selective immunoproteasome inhibitor 53 Phase 2b study 53 iobenguane 53 herpetic keratitis 53 Levetiracetam 53 ERYtech Pharma 53 Phase IIa trial 53 HCV protease 53 Eltrombopag 53 UPLYSO 53 EZN 53 Campath ® 53 HMPL 53 Pivotal Phase III 53 Cloretazine ® 53 PRLX # 53 BMN 53 therapeutic monoclonal antibodies 53 Antisense Pharma 53 Phase 2a Clinical Trial 53 Fibrex Medical 53 NOX E# 53 Restanza 53 small molecule inhibitor 53 Indaflex TM 53 QLT# 53 Idera Pharmaceuticals 53 Seliciclib 53 delta opioid receptor 53 investigational oral 53 Mersana 53 BNC# 53 mitogen activated ERK kinase 53 Phase 2b Clinical Trial 53 MEK inhibitor ARRY 53 Dacogen decitabine 53 KNS # 53 Opexa 53 forodesine 53 Anavex #-# 53 Phase #b/#a clinical 53 Phase 2b clinical 53 Panzem R 53 metastatic hormone refractory 53 Igeneon 53 DB# [003] 53 synthetic retinoid 53 BCR ABL inhibitors 53 Portola Pharmaceuticals 53 Syncria 53 Unit Dose Budesonide 53 Phase IIb clinical 53 MVA BN R 53 Nippon Shinyaku 53 BLP# Liposome Vaccine 53 ATL# [002] 53 epothilones 53 MOLOGEN 53 Arisaph 53 selective adenosine 53 BiTE antibody 53 APEX PD 53 rFIXFc 53 HCV protease inhibitors 53 nitric oxide donating 53 AFFiRiS 53 Phase Ia 53 DOS# 53 chimeric monoclonal antibody 53 Amigal 53 OncoMed 53 Peregrine Pharma 53 Zalbin 53 SAR# [002] 53 motesanib diphosphate 53 PORxin TM 53 Viprinex 53 Bendamustine 53 IMiDs R 53 Corlux 53 metastatic RCC 53 Akela Pharma 53 Ocrelizumab 53 SAR# [004] 52 midstage clinical 52 Loramyc R 52 Ozarelix 52 preclinical 52 CA4P 52 Arranon 52 MacroChem 52 Initiate Phase 52 ceftazidime 52 ongoing Phase 1b 52 Orexo 52 vascular disrupting agents 52 selective androgen receptor modulators 52 sorafenib Nexavar 52 receptor agonist 52 Tranzyme 52 #D#C# 52 CGEN # 52 XL# XL# XL# 52 ceftaroline 52 phase 2a 52 Sosei 52 Vivalis 52 Tezampanel 52 beta 1a 52 compound ITMN 52 Targretin 52 intranasal formulation 52 Phase III clinical 52 selectin antagonist 52 Addex 52 Phase IIIb clinical 52 DNA intercalator 52 FoldRx 52 Spiegelmer ® 52 talactoferrin 52 JAK2 inhibitor 52 Lixisenatide 52 Receptos 52 HDACi 52 glufosfamide 52 R roscovitine 52 Ceflatonin R 52 dimebon 52 tumor vascular disrupting 52 Jerini 52 Arqule 52 Logical Therapeutics 52 L BLP# 52 dexpramipexole 52 ILUVIEN ® 52 palifosfamide 52 kinase inhibitor 52 IgG1 monoclonal antibody 52 PrevOnco ™ 52 IDX# 52 Santaris 52 interferon gamma 1b 52 MOLOGEN AG 52 ZACTIMA 52 Euroscreen 52 Stapled Peptide 52 Emisphere Technologies 52 virus HCV protease inhibitor 52 multicenter Phase II 52 EyeGate Pharma 52 Phase #b/#a 52 Randomized Phase 52 JP-#/fipamezole 52 HCV NS5B polymerase 52 cetuximab Erbitux R 52 Junovan TM 52 afatinib 52 dalbavancin 52 Protexia R 52 Bremelanotide 52 custirsen 52 SinuNase ™ 52 mTOR inhibitor 52 Teikoku Pharma USA 52 ZP# [002] 52 GlycoPEG GCSF 52 Biotie 52 Proxinium TM 52 angiogenesis inhibitor 52 Alzhemed TM 52 ImmunoGen Inc. 52 Phase 2a clinical 52 HDAC inhibitor 52 cannabinor 52 Chemokine 52 DAVANAT ® 52 phase Ib clinical 52 evaluating tivozanib 52 Pharmacokinetics PK 52 gefitinib Iressa 52 E1 INT TM 52 DIREVO 52 Peregrine Pharmaceuticals 52 ThGRF 52 Ophthotech 52 trastuzumab DM1 52 elesclomol 52 Photocure 52 ThromboGenics 52 Ecallantide 52 Phase 2b Study 52 ProBioGen 52 partial agonist 52 BioNumerik 52 Afatinib 52 recombinant human 52 romidepsin 52 eprotirome 52 RH1 52 AVN# [001] 52 initiated Phase 1b 52 Bosutinib 52 CD3 monoclonal antibody 52 targeted antifolate 52 IL# PE#QQR 52 ONTAK 52 Clofarabine 52 teduglutide 52 Zorbtive TM 52 Anticalin ® 52 vilazodone 52 Can Fite 52 octreotide acetate 52 ARIKACE ™ 52 INCB# [002] 52 ZK EPO 52 novel topoisomerase 52 Velcade bortezomib 52 Pyridorin 52 PLK1 SNALP 52 alefacept 52 Eurand 52 EFAPROXYN 52 JZP 52 Locteron ® 52 Prodarsan R 52 MTP inhibitor 52 cyclin dependent kinase CDK 52 phase IIb study 52 TKB# 52 investigational pan BCR 52 Romidepsin 52 sodium glucose cotransporter 52 leading oral taxane 52 small molecule thrombopoietin 52 Talotrexin 52 Hana Biosciences 52 Trimesta 52 LB# [003] 52 Keryx Biopharma 52 tesetaxel 52 SCY 52 Squalamine 52 ENMD 52 Phenoptin 52 Graffinity Pharmaceuticals 52 P#X# antagonist 52 Resolvyx 52 WILEX AG 52 Chemokine Therapeutics 52 Cethrin 52 Prodarsan ® 52 Memryte 52 CA9 SCAN 52 ProMune 52 Poly ICLC 52 Solulin 52 Hedgehog antagonist 52 INC# 52 CytoFab 52 XL# XL# 52 CytoFabTM 52 Neurobiological Technologies 52 Cannabinor 52 PRX # 52 dasatinib Sprycel ® 52 SCHWARZ PHARMA 52 CVac 52 Ceflatonin 52 Phase 2b Trial 52 investigational compound 52 Perifosine 52 Epothilones 52 PS# [001] 52 Aegera Therapeutics 52 Apeiron Biologics 52 DXL# 52 exon skipping 52 novel prodrug 52 HepeX B 52 Sunesis Pharma 52 Intendis 52 DeveloGen 52 Syndax 52 CD# CEA 52 gemcitabine Gemzar ® 52 investigational monoclonal antibody 52 RhuDex 52 Aurexis 52 Huntexil 52 SR Pharma 52 Biopartners 52 MNTX 52 Genentech Roche 52 NexACT 52 Davanat 52 Zenvia Phase III 51 VAPRISOL 51 allosteric modulation 51 Phase IIB 51 oral formulation 51 Cerimon 51 pediatric acute lymphoblastic 51 PharmaMar 51 PI3K/Akt pathway inhibitor 51 celgosivir 51 CDK inhibitor 51 StemEx 51 voclosporin 51 adenosine A2A 51 APF# 51 Japanese Encephalitis vaccine 51 seliciclib 51 fostamatinib 51 PEGylated interferon 51 Fc fusion protein 51 ANG# 51 CRLX# 51 Dasatinib 51 Aerosurf 51 controlled multicenter Phase 51 Minapharm 51 investigational drug 51 Bortezomib 51 Factor VIIa 51 samalizumab 51 microplasmin Phase III 51 ara C 51 Arimoclomol 51 trastuzumab DM1 T DM1 51 Talactoferrin 51 deforolimus 51 Regeneron Pharma 51 small molecule chemotherapeutic 51 FTY# fingolimod 51 HuMax TAC 51 Vaccinex 51 AFFiRiS GmbH 51 Plicera 51 Phase IIb Trial 51 telomerase therapeutic 51 pivotal Phase III 51 EOquin 51 ACHN 51 Onco TCS 51 Hsp# Inhibitor 51 APOPTONE 51 PRIALT 51 Kinase Inhibitor 51 Gleevec resistant 51 novel anticancer 51 Arcalyst 51 tranilast 51 Oramed 51 StromaCel Inc. 51 TheraQuest 51 Nanobodies 51 orally administered 51 Telatinib 51 ISTODAX 51 CDP# 51 Successfully Completes Phase 51 Ganciclovir 51 Regado Biosciences 51 NPC 1C 51 Innate Pharma 51 PNT# 51 VEGF receptor 51 Gastrotech 51 Sigma Tau SpA 51 tafamidis 51 IV Busulfex 51 ZARS Pharma 51 pharmacodynamic properties 51 PDX pralatrexate 51 Preclinical studies 51 daclizumab 51 Firazyr 51 Phynova 51 Pervasis 51 Tamibarotene 51 Janus Kinase 51 Troxatyl TM 51 PEG PAL 51 Nitec 51 VIVALIS 51 DDP# 51 HuMax HepC TM 51 Neuraltus 51 nucleotide analog 51 Adnectin 51 perifosine 51 EXPAREL TM 51 selective inhibitor 51 Karo Bio 51 highly selective inhibitor 51 Cimzia ® 51 TMC# [002] 51 TLR9 agonists 51 HSP# inhibitor 51 ProtAffin 51 MBP# [001] 51 Phase 2b 51 Silodosin 51 tezampanel 51 Pharmexa 51 Agennix 51 PAION 51 Pafuramidine 51 Anticalins R 51 ALGRX 51 Pevion 51 methylnaltrexone 51 CCX# B 51 novel VDA molecule 51 non nucleoside 51 diabetic neuropathic pain 51 Personalized Immunotherapy 51 Paion 51 vosaroxin 51 Prosensa 51 Kiadis Pharma 51 alemtuzumab Campath 51 RG# ITMN 51 Signature Diagnostics 51 oral JAK#/JAK# inhibitor 51 aflibercept 51 Alvesco R 51 GRN# 51 Toctino ® alitretinoin 51 anidulafungin 51 R#/MEM 51 Phase IIb trial 51 SUTENT ® 51 Fx #A 51 RegeneRx Biopharmaceuticals 51 GVAX 51 IMC #B 51 Liposomal 51 histamine dihydrochloride 51 OncoVEX 51 TOPIGEN 51 CORT # 51 dSLIM 51 TRACON Pharmaceuticals 51 tyrosine kinase inhibitor 51 zanolimumab 51 AMEX ONI 51 Xyfid TM 51 2 methoxyestradiol 51 Zerenex ™ 51 sargramostim 51 Nimotuzumab 51 sunitinib malate 51 Anidulafungin 51 Cariprazine 51 #ME# 51 ASA# 51 amrubicin 51 Teriflunomide 51 Elvitegravir 51 cell lymphoma CTCL 51 POTELLIGENT R Technology 51 D Pharm 51 GSK# [002] 51 IMMU 51 Novelos 51 Anaphore 51 Apitope 51 POTELLIGENT ® 51 highly selective endothelin 51 Phase #b/#a trial 51 ELND# AZD 51 lixivaptan 51 daptomycin 51 erlotinib Tarceva ® 51 tiapamil 51 G#DT 51 Innovive 51 Icatibant 51 candidate REP# 51 OvaRex R 51 Ulrich Dauer CEO 51 DPX Survivac 51 proprietary polysaccharide 51 darinaparsin ZIO 51 Prodarsan 51 novel mTOR inhibitor 51 IIa trial 51 Phase III 51 Enobia 51 subcutaneous formulation 51 NovImmune 51 peptibody 51 protein kinase inhibitor 51 Lodotra 51 Urocidin 51 Cutanea Life Sciences 51 selective kinase inhibitor 51 Tasimelteon 51 CRF1 receptor antagonist 51 lupus nephritis 51 rPA anthrax vaccine 51 ESBATech AG 51 Potelligent Technology 51 Adenosine Therapeutics 51 ketolide antibiotic 51 Hybridon 51 MKC# MT 51 luteinizing hormone releasing 51 castrate resistant prostate cancer 51 Vegenics 51 Zenvia ™ 51 Phase 1a clinical 51 Anticalins ® 51 Phase III Clinical Trial 51 MEDI 51 pharmacological chaperone 51 ADVEXIN 51 Creabilis Therapeutics 51 Vicriviroc 51 5 HT2A inverse 51 Evotec OAI 51 ImmunGene